Project Grant HT94252310215
Award Date 7/1/23
Completion Date 6/30/25
Dollars Obligated $254K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The Defense Health Agency awarded a $1,318,799.00 Project Grant to Brigham & Women's Hospital Inc. in Boston, MA on June 15, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "THE BRIDGE PROJECT: BROADENING THE REACH OF IMAGING, DIAGNOSTICS, AND GENETIC EVALUATION", will fund research and development to transform healthcare for U.S. military service members and the public through innovative medical solutions for the battlefield and...
- The Department of the Army Medical Command awarded a $1,715,894 project grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program. The grant will fund research from August 1, 2022 to July 31, 2025 to target tuberous sclerosis complex (TSC) by developing mTORC1-specific bi-steric inhibitors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and...
- This federal Project Grant award of $855,709.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Brigham & Women's Hospital Inc. to target mitochondrial metabolism in Tuberous Sclerosis Complex. The 3-year project, running from September 1, 2023 to August 31, 2026, aims to transform healthcare for Service Members and the American public through innovative and impactful biomedical research on this rare...
- The Defense Health Agency awarded a $682,266 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2024. The grant supports research to develop targeted endothelial cell-derived extracellular vesicle nanoparticles for immunotherapy against brain cancer, with a performance period ending on May 14, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive...
- Brigham & Women's Hospital Inc. was awarded a $379,876 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2023 through August 31, 2026 to investigate whether microbiome-derived cell fragments in the brain can accelerate the transition from traumatic brain injury to Alzheimer's disease or related dementias. As the direct awardee, Brigham & Women's Hospital will leverage...
- The Department of the Army Medical Command awarded Brigham & Women's Hospital Inc. a $648,276 Project Grant under the Military Medical Research and Development program. The three-year award will fund research from September 2022 to September 2025 to target TFEB and TFE3 in renal tumorigenesis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and public health care through innovative...
- The federal Project Grant award for $236,072 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to evaluate the efficacy of novel B7-H3 antibodies in tuberous sclerosis complex (TSC). The awardee, Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, will conduct this biomedical research project over a 2-year period from August 1, 2024 to July 31, 2026. As a leading academic medical center, Brigham...
- This $1,683,194 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research by Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System) to investigate the role of the glycome in identifying biomarkers and understanding the molecular pathogenesis of tuberous sclerosis complex (TSC). The award has a performance period from August 1, 2025 to July 31, 2028 and will enable...
- The U.S. Defense Health Agency awarded Brigham & Women's Hospital Inc. a $653,343 Project Grant under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to identify novel therapeutic strategies for chromophobe renal cell carcinoma. The three-year project, with a period of performance from Sep 30, 2023 to Sep 29, 2026, will focus on basic and applied biomedical research to develop innovative treatments for this rare form of kidney cancer. As a...
- Brigham & Women's Hospital Inc. was awarded a $596,016 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 1, 2023 to August 31, 2027 to investigate environmental and gut-brain axis determinants of cognitive outcomes in Parkinson's disease. As the primary awardee, Brigham & Women's Hospital will leverage its expertise in biomedical research and healthcare services...